Presentation Information
[O1-4-10]Short-course treatment with the hepato-selective dihydroquinolizinone HS83128 prevents hepatitis A following oral HAV challenge in mice
*Ichiro Misumi1, Jason K. Whitmire1,2,3, Timothy Block4,5, Stanley M. Lemon2,3,6, Yanming Du4,5, You Li7 (1. Dept. of Genetics, University of North Carolina at Chapel Hill, NC, USA, 2. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC, USA, 3. Dept. of Microbiology & Immunology, University of North Carolina at Chapel Hill, NC, USA, 4. Baruch S. Blumberg Institute, PA, USA, 5. Harlingene Life Sciences, PA, USA, 6. Dept. of Medicine, University of North Carolina at Chapel Hill, NC, USA, 7. Dept. of Pediatrics, University of North Carolina at Chapel Hill, NC, USA)
